OnKure Therapeutics, Inc. (OKUR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $108.33M
Last updated: Nov 17, 2026 at 11:05 AM ET
OnKure Therapeutics, Inc. (OKUR) Earnings: Report Dates and Results
OnKure Therapeutics (OKUR) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, OnKure Therapeutics reported EPS of -$0.36, below the -$0.29 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OKUR has an expected report date of Mar 10, 2027.
Earnings History
Of the 9 quarters below that had an estimate, OKUR beat 6 and missed 3. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 57.47% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.36 | -$0.29 | -$0.62 - -$0.29 | -24.14% | Miss | N/A | 4 | 1 up, 0 down | Nov 4, 2026 |
| Jun 30, 2026 | -$0.31 | -$0.58 | -$0.77 - -$0.39 | +46.55% | Beat | N/A | 4 | 0 up, 0 down | Aug 4, 2026 |
| Mar 31, 2026 | -$1.11 | -$0.74 | -$1.05 - -$0.39 | -50.00% | Miss | N/A | 4 | 2 up, 0 down | May 5, 2026 |
| Dec 31, 2025 | -$0.99 | -$1.15 | -$1.25 - -$1.03 | +14.06% | Beat | N/A | 5 | 2 up, 1 down | Mar 12, 2026 |
| Sep 30, 2025 | -$1.09 | -$1.20 | -$1.22 - -$1.09 | +9.17% | Beat | N/A | 5 | 4 up, 0 down | Nov 6, 2025 |
| Jun 30, 2025 | -$1.14 | -$1.25 | N/A | +8.80% | Beat | N/A | N/A | N/A | Aug 12, 2025 |
| Mar 31, 2025 | -$1.19 | -$1.38 | N/A | +14.04% | Beat | N/A | 3 | 0 up, 0 down | May 6, 2025 |
| Dec 31, 2024 | -$1.37 | -$0.87 | -$1.10 - -$0.38 | -57.47% | Miss | N/A | 4 | 0 up, 0 down | Mar 10, 2025 |
| Sep 30, 2024 | -$0.86 | -$0.90 | N/A | +4.44% | Beat | N/A | N/A | N/A | Nov 7, 2024 |
| Jun 30, 2024 | -$1.60 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2024 |
| Mar 31, 2024 | -$2.52 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2024 |
| Dec 31, 2023 | -$7.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 28, 2024 |
| Sep 30, 2023 | -$5.68 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2023 |
| Jun 30, 2023 | -$6.46 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2023 |
| Mar 31, 2023 | -$6.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2023 |
| Dec 31, 2022 | -$5.54 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 27, 2023 |
| Sep 30, 2022 | -$5.31 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 8, 2022 |
| Jun 30, 2022 | -$5.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 9, 2022 |
| Mar 31, 2022 | -$5.33 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2022 |
| Dec 31, 2021 | -$4.34 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 24, 2022 |
| Sep 30, 2021 | -$5.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 12, 2021 |
| Jun 30, 2021 | -$4.31 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2021 |
| Mar 31, 2021 | -$2.97 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 20, 2021 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$4.41, after -$6.36 the year before. It was -$16.84 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$4.41 | N/A |
| Dec 31, 2024 | -$6.36 | N/A |
| Dec 31, 2023 | -$25.22 | N/A |
| Dec 31, 2022 | -$21.21 | N/A |
| Dec 31, 2021 | -$16.84 | N/A |
Frequently Asked Questions About OKUR
When is OnKure Therapeutics's next earnings date?
OnKure Therapeutics's next earnings report is expected for Mar 10, 2027.
Did OKUR beat earnings estimates last quarter?
No. OnKure Therapeutics reported EPS of -$0.36 for the quarter ended Sep 30, 2026, below the -$0.29 estimate by 24.14%.
What EPS do analysts expect from OKUR next quarter?
The consensus EPS estimate for OnKure Therapeutics for the quarter ending Dec 31, 2026 is -$0.39 from 6 analysts, with estimates from -$0.43 to -$0.36.
How often does OKUR beat earnings estimates?
OnKure Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -4.87%.
OKUR pages: Overview, Earnings, Forecast, Financials, Competitors